The study finds a molecular pathway to explain patterns long observed by those who work with patients being treated for both alcohol abuse and depression.
The connection between alcohol abuse and depression has been noted for years among those who work with patients affected by the disorders, leading to the hypothesis that many were “self-medicating” to relieve symptoms.
A new study published in Nature Communications plots out that biochemical path for the first time, using mouse models to show that alcohol produces the same effect seen in newer rapid-acting antidepressants, such as ketamine, which bring lasting relief in hours. The effects of alcohol on depression take effect quickly and can last up to 24 hours, the study found.
For years, one of the challenges in treating depression has been the fact that many therapies take up to 2 weeks to build up in a patient’s system before there is a noticeable effect; this can lead some patients to believe the drugs don’t work, or patients can continue to suffer severe symptoms while waiting for relief.
For patients trying to stop alcohol abuse, it’s especially difficult if the substance is providing the only respite from symptoms, and there is a gap before relief from pharmacotherapy occurs.
In working with the mouse models, researchers examined how alcohol behaved on the same molecular pathway that is activated by rapid antidepressants, according to lead author Kimberly Raab-Graham, PhD, associate professor of physiology and pharmacology at Wake Forest School of Medicine.
Ethanol created the same receptor response as the rapid antidepressants—an alteration of GABABR expression and signaling. Further work showed the effect that alcohol has on fragile-X mental retardation protein, or FMRP, as shown by experiments with “knockout” mice who were missing the protein. Thus, this protein was confirmed as a key regulator for the antidepressant effect of acute ethanol exposure.
The researchers wrote that the presence of major depression doubles the risk of alcohol use, and the reverse is also true. While more work is needed, the findings offer a biological reason “for the natural human instinct to self-medicate,” Raab-Graham said. “They also define a molecular mechanism that may be a critical contributor to the comorbidity that occurs with alcohol use disorder and major depressive disorder.”
Reference
Wolfe SA, Workman ER, Heaney CF, et al. FMRP regulates an ethanol-dependent shift in GABABR function and expression with rapid antidepressant properties. Nature Comms 2016;712867. doi:10.1038.ncomms12867.
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More